Corvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on Monday

Posted by Bonnie Powley on May 4th, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Monday, May 6th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.12) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported ($0.14) EPS for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, analysts expect Corvus Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Performance

CRVS opened at $1.92 on Friday. Corvus Pharmaceuticals has a one year low of $1.05 and a one year high of $4.19. The stock has a market capitalization of $94.15 million, a P/E ratio of -3.37 and a beta of 1.05. The business’s 50-day simple moving average is $1.80 and its 200-day simple moving average is $1.77.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRVS. Mizuho reaffirmed a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Finally, Oppenheimer lowered their target price on Corvus Pharmaceuticals from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 20th.

Check Out Our Latest Stock Analysis on Corvus Pharmaceuticals

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.